Biofrontera AG's total inventories for the quarter that ended in Mar. 2026 was €3.55 Mil. Biofrontera AG's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was €3.65 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Biofrontera AG's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was €0.74.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Biofrontera AG's Days Inventory for the
three
months ended in Mar. 2026 was 469.76.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Biofrontera AG's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.19.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Biofrontera AG's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.98.
Biofrontera AG (FRA:B8FK) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Biofrontera AG's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Biofrontera AG's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Biofrontera AG Total Inventories Related Terms
Biofrontera AG Total Inventories Historical Data
* Premium members only.
The historical data trend for Biofrontera AG's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Biofrontera AG (FRA:B8FK) has a Total Inventories of €3.55 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Biofrontera AG and its competitors.
Is Biofrontera AG's Total Inventories too high?
Biofrontera AG's current Total Inventories is €3.55 Mil. Overall, Biofrontera AG has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biofrontera AG's Total Inventories compare to ZTS and UTHR?
Biofrontera AG's Total Inventories of €3.55 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Drug Manufacturers company?
A good Total Inventories depends on the Drug Manufacturers industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Biofrontera AG and its competitors. Biofrontera AG's current Total Inventories is €3.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofrontera AG stock overvalued right now?
Based on GuruFocus' analysis, Biofrontera AG (FRA:B8FK) is currently considered Fairly Valued. The stock's GF Value™ is €2.29, compared to a current price of €2.21 — trading 3.5% below its estimated fair value. The current Total Inventories is €3.55 Mil. Biofrontera AG's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Biofrontera AG (FRA:B8FK), the current Total Inventories is €3.55 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biofrontera AG (FRA:B8FK) Overvalued in 2026?
Based on GuruFocus' analysis, Biofrontera AG stock appears to be undervalued.
The current stock price of €2.21 is trading 3.5% below its estimated GF Value™ of €2.29.
GuruFocus considers Biofrontera AG to be Fairly Valued.
Key valuation signals for FRA:B8FK:
Total Inventories: €3.55 Mil
GF Value™: €2.29 vs. price of €2.21 (3.5% below fair value)
No single metric tells the full story. See the FRA:B8FK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED and BF-RhodoLED XL, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin. Geographically, the company generates maximum revenue from Germany, and the rest from Spain, the United Kingdom, the rest of Europe, and other regions.
58GF Score
Get the complete analysis for FRA:B8FK
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:B8FK has been successfully added to your 
